<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01349868</url>
  </required_header>
  <id_info>
    <org_study_id>PT005003</org_study_id>
    <nct_id>NCT01349868</nct_id>
  </id_info>
  <brief_title>PT005 MDI Dose Ranging Versus Foradil Aerolizer Study</brief_title>
  <official_title>A Randomized, Double-Blind, Single Dose, Six-Treatment, Placebo-Controlled, Cross-Over, Multi-Center Study to Assess Efficacy and Safety of Three Doses of PT005, in Patients With Moderate to Severe COPD, Compared With Foradil® Aerolizer® (12 and 24 µg Open-Label) as Active Controls</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pearl Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pearl Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and efficacy of inhaled PT005 MDI
      compared to placebo and Foradil Aerolizer in patients with moderate to severe chronic
      obstructive pulmonary disease (COPD).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2011</start_date>
  <completion_date type="Actual">July 2011</completion_date>
  <primary_completion_date type="Actual">July 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in FEV1 AUC0-12 from test day baseline across the three doses of inhaled PT005 compared with placebo</measure>
    <time_frame>1 Day</time_frame>
    <description>The primary objective of this study is to demonstrate efficacy relative to placebo of PT005 MDI in patients with moderate to severe chronic obstructive pulmonary disease (COPD) within the range of doses evaluated in this study. To this end, each dose of PT005 MDI will be compared to placebo with respect to the primary efficacy endpoint, the change in FEV1 AUC0-12 from baseline.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Characterize the dose-response curve of PT005 MDI</measure>
    <time_frame>1 Day</time_frame>
    <description>The secondary objective of the study is to characterize the dose-response curve of PT005 MDI, to conduct a non-inferiority assessment comparing PT005 MDI within the range of doses evaluated in this study to open-label Foradil Aerolizer 12 µg, and to select the most appropriate dose of PT005 MDI to carry forward into Phase III clinical studies</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety measures including electrocardiograms (ECGs), vital signs, physical exam, clinical laboratory testing, and adverse events</measure>
    <time_frame>1 Day</time_frame>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Chronic Obstructive Pulmonary Disease</condition>
  <arm_group>
    <arm_group_label>PT005 MDI (Dose 1)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PT005 MDI (Dose 1)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PT005 MDI (Dose 2)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PT005 MDI (Dose 2)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PT005 MDI (Dose 3)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PT005 MDI (Dose 3)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo MDI</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo MDI</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Formoterol Fumarate 12 μg (Foradil® Aerolizer®)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Formoterol fumarate inhalation powder 12 μg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Formoterol Fumarate 24 μg (Foradil® Aerolizer®)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Formoterol fumarate inhalation powder 24 μg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PT005 MDI</intervention_name>
    <description>PT005 MDI taken as two inhalations</description>
    <arm_group_label>PT005 MDI (Dose 1)</arm_group_label>
    <arm_group_label>PT005 MDI (Dose 2)</arm_group_label>
    <arm_group_label>PT005 MDI (Dose 3)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Formoterol Fumarate 12 μg (Foradil® Aerolizer®)</intervention_name>
    <description>Taken as 1 capsule. Each capsule contains 12 μg corresponding to 10 µg formoterol fumarate dihydrate delivered from the mouthpiece</description>
    <arm_group_label>Formoterol Fumarate 12 μg (Foradil® Aerolizer®)</arm_group_label>
    <other_name>Foradil® Aerolizer®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Formoterol Fumarate 24 μg (Foradil® Aerolizer®)</intervention_name>
    <description>Taken as 2 capsules. Each capsule contains 12 μg corresponding to 10 µg formoterol fumarate dihydrate delivered from the mouthpiece</description>
    <arm_group_label>Formoterol Fumarate 24 μg (Foradil® Aerolizer®)</arm_group_label>
    <other_name>Foradil® Aerolizer®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo MDI</intervention_name>
    <description>Matching placebo to PT005 MDI taken as two inhalations</description>
    <arm_group_label>Placebo MDI</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          -  Signed written informed consent

          -  40 - 80 years of age

          -  Clinical history of COPD with airflow limitation that is not fully reversible

          -  Females of non-child bearing potential or females of child bearing potential with
             negative pregnancy test; and acceptable contraceptive methods

          -  Current/former smokers with at least a 10 pack-year history of cigarette smoking

          -  A measured post- bronchodilator FEV1/FVC ratio of &lt; or = 0.70

          -  A measured post- bronchodilator FEV1 &gt; or = 750ml or 30% predicted and &lt; or = 80% of
             predicted normal values

          -  Able to change COPD treatment as required by protocol

          -  Demonstratead reversibility to short acting beta agonist (Ventolin HFA) (&gt; 12% and
             &gt;150 mL improvement in baseline FEV1 approximately 30 minutes following administration
             of 4 puffs of Ventolin HFA or &gt; 200 mL improvement in baseline FEV1 30 minutes
             following administration of 2 puffs of Ventolin HFA)

        Key Exclusion Criteria:

          -  Women who are pregnant or lactating

          -  Primary diagnosis of asthma

          -  Alpha-1 antitrypsin deficiency as the cause of COPD

          -  Active pulmonary diseases

          -  Prior lung volume reduction surgery

          -  Abnormal chest X-ray (or CT scan) not due to the presence of COPD

          -  Hospitalized due to poorly controlled COPD within 3 months of Screening

          -  Clinically significant medical conditions that preclude participation in the study
             (e.g. clinically significant abnormal ECG, uncontrolled hypertension, glaucoma,
             symptomatic prostatic hypertrophy)

          -  Cancer that has not been in complete remission for at least 5 years

          -  Treatment with investigational study drug or participation in another clinical trial
             or study within the last 30 days or 5 half lives

        Other inclusion/exclusion criteria as defined by the protocol
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Clearwater</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Spartanburg</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 5, 2011</study_first_submitted>
  <study_first_submitted_qc>May 6, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 9, 2011</study_first_posted>
  <disposition_first_submitted>September 10, 2012</disposition_first_submitted>
  <disposition_first_submitted_qc>September 10, 2012</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">September 12, 2012</disposition_first_posted>
  <last_update_submitted>September 10, 2012</last_update_submitted>
  <last_update_submitted_qc>September 10, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 12, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>COPD</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Formoterol Fumarate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

